DEFA14A: LENZ Therapeutics Announces Annual Stockholders Meeting and Director Nominations

LENZ Therapeutics will hold its annual stockholders meeting on June 10, 2025, to elect directors and ratify the appointment of Ernst & Young LLP as the independent auditor.

Summary

• LENZ Therapeutics, Inc. is holding its annual meeting of stockholders on June 10, 2025.
• The meeting will be held live via the internet.
• Stockholders of record as of April 14, 2025, are eligible to vote.
• The proposals include electing two Class III directors to hold office until the 2027 annual meeting and two Class I directors to hold office until the 2028 annual meeting.
• The nominees for Class III directors are Kimberlee C. Drapkin and Zach Scheiner.
• The nominees for Class I directors are Frederic Guerard and James McCollum.
• The stockholders will also vote to ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Sentiment

Score: 5

Explanation: The document is a standard proxy statement, indicating a neutral sentiment.

Positives

• The company is adhering to corporate governance practices by holding an annual meeting and allowing shareholders to vote on key decisions.

Future Outlook

The document outlines the standard procedures for an upcoming annual meeting, with no specific forward-looking financial statements.

Industry Context

This announcement is standard practice for publicly traded companies, ensuring compliance with SEC regulations and providing shareholders the opportunity to participate in corporate governance.

Stakeholder Impact

• Shareholders have the opportunity to vote on the election of directors and the ratification of the auditor.
• The outcome of the votes will influence the composition of the board and the selection of the auditing firm.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will proceed with the annual meeting on June 10, 2025.

Key Dates

Keywords

Annual Meeting, Stockholders, Directors, Proxy Statement, LENZ Therapeutics, Ernst & Young, Auditor